Last reviewed · How we verify
Methylphenidate, aripiprazole, and combination
This combination uses methylphenidate to increase dopamine and norepinephrine activity, while aripiprazole acts as a dopamine partial agonist to modulate psychotic symptoms and mood.
This combination uses methylphenidate to increase dopamine and norepinephrine activity, while aripiprazole acts as a dopamine partial agonist to modulate psychotic symptoms and mood. Used for Attention-deficit/hyperactivity disorder (ADHD) with comorbid psychotic or mood symptoms, Schizophrenia or schizoaffective disorder with attention deficits.
At a glance
| Generic name | Methylphenidate, aripiprazole, and combination |
|---|---|
| Also known as | Ritalin/Concerta, Abilify, and combination |
| Sponsor | Tri-Service General Hospital |
| Drug class | Stimulant and atypical antipsychotic combination |
| Target | Dopamine transporter (DAT), norepinephrine transporter (NET), dopamine D2 receptor (partial agonist), serotonin 5-HT1A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
Methylphenidate is a stimulant that blocks the reuptake of dopamine and norepinephrine, increasing their synaptic availability and enhancing attention and executive function. Aripiprazole is an atypical antipsychotic that acts as a partial agonist at dopamine D2 receptors and serotonin 5-HT1A receptors, providing antipsychotic and mood-stabilizing effects. The combination is used to address both attention deficits and psychotic or mood symptoms in patients who require both therapeutic actions.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD) with comorbid psychotic or mood symptoms
- Schizophrenia or schizoaffective disorder with attention deficits
Common side effects
- Insomnia
- Headache
- Nausea
- Tachycardia
- Akathisia
- Weight gain
- Anxiety
Key clinical trials
- Measurement of Treatment Effects (EARLY_PHASE1)
- Irritability in Children With ADHD and Emotion Dysregulation (PHASE4)
- Aripiprazole Added on for DMDD in Youths With ADHD (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: